$RDTCF $DOSE.CN Rapid Dose Therapeutics (DOSE) (RDTCF) Advances Pharmaceutical Manufacturing Expansion with Burlington Facility Upgrades Targeting Global Medical Markets
https://www.newsfilecorp.com/release/292167/R...al-Markets
Burlington, Ontario--(Newsfile Corp. - April 13, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) ("RDT" or the "Company"
, a Canadian biotechnology company developing oral thin film drug delivery technologies, today announced the initiation of clean room upgrades and facility retrofitting at its Burlington, Ontario manufacturing site, positioning the Company for pharmaceutical expansion, regulatory advancement, and global commercialization opportunities.
The upgrade program is focused on advancing the facility toward compliance with Health Canada Drug Establishment Licence (DEL) requirements, a critical regulatory pathway for companies engaged in the manufacturing, packaging, testing, distribution, and commercialization of pharmaceutical products in Canada. These enhancements are expected to support production of products requiring a Drug Identification Number (DIN), a key authorization for prescription and over-the-counter drug sales in regulated markets.
Strategic Move Into Pharmaceutical Manufacturing and Global Drug Markets
The Burlington facility upgrades mark a significant step in Rapid Dose Therapeutics' evolution from a drug delivery innovation company into a pharmaceutical manufacturing and commercialization platform. The initiative is designed to expand the Company's capabilities across oral thin film drug delivery, pharmaceutical production, and global distribution channels, supporting its proprietary QuickStrip™ fast-dissolving oral thin film technology.
QuickStrip™ is engineered to deliver pharmaceuticals, nutraceuticals, cannabinoids, vaccines and nicotine products through rapid absorption via the oral mucosa, offering advantages in bioavailability, onset time, and patient compliance compared to traditional capsules, tablets, injections and inhalation-based delivery systems.
GMP and EU GMP Alignment Supports International Expansion
In parallel, Rapid Dose is upgrading its existing cannabis production clean rooms to align with Good Manufacturing Practice (GMP) and European Union GMP (EU GMP) standards, reinforcing its readiness to participate in the rapidly expanding global medical cannabis and pharmaceutical export markets.
These upgrades are expected to enable:
Entry into regulated international pharmaceutical markets
Expansion of medical cannabis exports
Increased participation in high-growth non-smoking cannabis formats
Enhanced attractiveness for strategic partnerships and licensing agreements
The Burlington facility is being developed into a dual-purpose centralized manufacturing hub, capable of supporting both pharmaceutical-grade production and cannabis-based product manufacturing, creating operational efficiencies and long-term scalability.
As of the date of this release. no approvals have been obtained and timelines and outcomes are uncertain.
Positioned for Market Opportunities
The expansion aligns with major global market trends, including:
The global pharmaceutical market, projected to reach approximately $1.7 trillion by 2030
Canada's top 10 global pharmaceutical market position
The global medical cannabis market, projected to reach approximately $65.9 billion by 2030
These markets are being driven by rising demand for innovative drug delivery systems, patient-friendly dosing formats, and compliant manufacturing infrastructure.
Building a Scalable Platform for Long-Term Growth
"This upgrade represents a pivotal step in expanding the strategic value of our Burlington facility," said Mark Upsdell, CEO of Rapid Dose Therapeutics. "By aligning our operations with internationally recognized pharmaceutical standards, we are strengthening our ability to pursue high-growth commercial opportunities while scaling the global reach of our QuickStrip™ platform."
Upon completion, the upgraded facility is expected to deliver:
Expanded pharmaceutical manufacturing capabilities
Enhanced regulatory readiness (DEL, DIN pathways)
Improved operational efficiency and scalability
Stronger positioning for global partnerships and licensing deals
https://www.newsfilecorp.com/release/292167/R...al-Markets
Burlington, Ontario--(Newsfile Corp. - April 13, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) ("RDT" or the "Company"
, a Canadian biotechnology company developing oral thin film drug delivery technologies, today announced the initiation of clean room upgrades and facility retrofitting at its Burlington, Ontario manufacturing site, positioning the Company for pharmaceutical expansion, regulatory advancement, and global commercialization opportunities. The upgrade program is focused on advancing the facility toward compliance with Health Canada Drug Establishment Licence (DEL) requirements, a critical regulatory pathway for companies engaged in the manufacturing, packaging, testing, distribution, and commercialization of pharmaceutical products in Canada. These enhancements are expected to support production of products requiring a Drug Identification Number (DIN), a key authorization for prescription and over-the-counter drug sales in regulated markets.
Strategic Move Into Pharmaceutical Manufacturing and Global Drug Markets
The Burlington facility upgrades mark a significant step in Rapid Dose Therapeutics' evolution from a drug delivery innovation company into a pharmaceutical manufacturing and commercialization platform. The initiative is designed to expand the Company's capabilities across oral thin film drug delivery, pharmaceutical production, and global distribution channels, supporting its proprietary QuickStrip™ fast-dissolving oral thin film technology.
QuickStrip™ is engineered to deliver pharmaceuticals, nutraceuticals, cannabinoids, vaccines and nicotine products through rapid absorption via the oral mucosa, offering advantages in bioavailability, onset time, and patient compliance compared to traditional capsules, tablets, injections and inhalation-based delivery systems.
GMP and EU GMP Alignment Supports International Expansion
In parallel, Rapid Dose is upgrading its existing cannabis production clean rooms to align with Good Manufacturing Practice (GMP) and European Union GMP (EU GMP) standards, reinforcing its readiness to participate in the rapidly expanding global medical cannabis and pharmaceutical export markets.
These upgrades are expected to enable:
Entry into regulated international pharmaceutical markets
Expansion of medical cannabis exports
Increased participation in high-growth non-smoking cannabis formats
Enhanced attractiveness for strategic partnerships and licensing agreements
The Burlington facility is being developed into a dual-purpose centralized manufacturing hub, capable of supporting both pharmaceutical-grade production and cannabis-based product manufacturing, creating operational efficiencies and long-term scalability.
As of the date of this release. no approvals have been obtained and timelines and outcomes are uncertain.
Positioned for Market Opportunities
The expansion aligns with major global market trends, including:
The global pharmaceutical market, projected to reach approximately $1.7 trillion by 2030
Canada's top 10 global pharmaceutical market position
The global medical cannabis market, projected to reach approximately $65.9 billion by 2030
These markets are being driven by rising demand for innovative drug delivery systems, patient-friendly dosing formats, and compliant manufacturing infrastructure.
Building a Scalable Platform for Long-Term Growth
"This upgrade represents a pivotal step in expanding the strategic value of our Burlington facility," said Mark Upsdell, CEO of Rapid Dose Therapeutics. "By aligning our operations with internationally recognized pharmaceutical standards, we are strengthening our ability to pursue high-growth commercial opportunities while scaling the global reach of our QuickStrip™ platform."
Upon completion, the upgraded facility is expected to deliver:
Expanded pharmaceutical manufacturing capabilities
Enhanced regulatory readiness (DEL, DIN pathways)
Improved operational efficiency and scalability
Stronger positioning for global partnerships and licensing deals
